Kiniksa Pharmaceuticals International, plc (KNSA) - Dilution Analysis

Visualizing historical and potential share dilution over time

View Stock Details

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Dilution Analysis

Medium Risk

Moderate dilution risk

Last updated: April 28, 2026

Risk Assessment Details

Potential Dilution: 0.0% of current shares

Recent Dilution: 528.52% (2 years)

Historical Dilution Factor: significant recent dilution

Outstanding Shares

77M

Potential Supply

Additional shares possible

Splits

None

Past 2 years

Summary

KNSA currently has 76.5M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 528.52% over the past 2 years, indicating aggressive capital raising.

Share Structure Timeline

Outstanding Shares

Total Supply

Historical Data Points

Date	Event	Outstanding	Supply
Apr 28, 2026	10-Q filing \| 76.5M shares outstanding	77M	0
Oct 28, 2025	10-Q filing \| 74.7M shares outstanding	75M	0
Jul 29, 2025	10-Q filing \| 16.1M shares outstanding	16M	2M
Apr 29, 2025	10-Q filing \| 16.1M shares outstanding	16M	2M
Feb 25, 2025	10-K filing \| 41.9M shares outstanding	42M	0
Oct 29, 2024	10-Q filing \| 16.1M shares outstanding	16M	2M
Jul 25, 2024	10-Q filing \| 16.1M shares outstanding	16M	2M
Jun 28, 2024	S-3 filing: Kiniksa Pharmaceuticals International, PLC is filing an S-3 registration statement to offer and sell up to $400,000,000 in the aggregate of Class A Ordinary Shares, Preferred Shares, Debt Securities, Warrants, and Units from time to time in one or more offerings.	16M	2M
Jun 28, 2024	POS AM filing: This is a POS AM filing by Kiniksa Pharmaceuticals International, PLC relating to the proposed resale of up to 28,682,554 Class A ordinary shares by selling shareholders.	16M	2M
Jun 28, 2024	POS AM filing: This is a POS AM filing to register additional securities for an offering pursuant to Rule 462(b).	16M	2M
Apr 25, 2024	10-Q filing \| 16.1M shares outstanding	16M	31M
Feb 28, 2024	10-K filing \| 35.8M shares outstanding	36M	11M
Nov 02, 2023	10-Q filing \| 16.1M shares outstanding	16M	31M
Aug 01, 2023	10-Q filing \| 16.1M shares outstanding	16M	31M
May 04, 2023	10-Q filing \| 16.1M shares outstanding	16M	31M
Mar 02, 2023	10-K filing \| 34.8M shares outstanding	35M	12M
Nov 03, 2022	10-Q filing \| 16.1M shares outstanding	16M	31M
Aug 04, 2022	10-Q filing \| 16.1M shares outstanding	16M	31M
May 06, 2022	S-3 filing: Kiniksa Pharmaceuticals, Ltd. is filing a registration statement on Form S-3 to offer and sell up to $400,000,000 in the aggregate of Class A Common Shares, Preferred Shares, Debt Securities, Warrants, and Units from time to time in one or more offerings.	16M	31M
May 06, 2022	S-3 filing: Registration statement for the resale of Class A common shares by selling shareholders.	16M	31M
May 05, 2022	10-Q filing \| 16.1M shares outstanding	16M	2M
Feb 24, 2022	10-K filing \| 34.1M shares outstanding	34M	0
Nov 04, 2021	10-Q filing \| 16.1M shares outstanding	16M	2M
Aug 05, 2021	10-Q filing \| 16.1M shares outstanding	16M	2M
May 06, 2021	10-Q filing \| 18.0M shares outstanding	18M	56K
Feb 25, 2021	10-K filing \| 31.8M shares outstanding	32M	0
Nov 05, 2020	10-Q filing \| 16.1M shares outstanding	16M	2M
Sep 08, 2020	S-3 filing: This S-3 filing registers 1,484,727 Class A common shares for resale by selling shareholders.	16M	2M
Aug 04, 2020	10-Q filing \| 16.1M shares outstanding	16M	540K
Jul 24, 2020	8-K filing: Kiniksa Pharmaceuticals, Ltd. completed a public offering of 5,952,381 Class A common shares at $21.00 per share and a concurrent private placement of 1,428,572 non-voting Class A1 common shares to Baker Bros. Advisors LP at $21.00 per share. ($30.0M proceeds)	15M	1.6M
May 21, 2020	S-3 filing: This S-3 filing from Kiniksa Pharmaceuticals, Ltd. relates to the proposed resale of up to 1,600,000 Class A common shares by selling shareholders, issuable upon conversion of Class A1 common shares. The company will not receive any proceeds from the sale.	15M	1.6M
May 18, 2020	8-K filing: Kiniksa Pharmaceuticals, Ltd. completed a public offering of 2,760,000 Class A common shares at $18.25 per share and a private placement of 1,600,000 non-voting Class A1 common shares to Baker Bros. Advisors LP at $18.25 per share on May 18, 2020. ($29.2M proceeds)	15M	0
May 04, 2020	10-Q filing \| 15.0M shares outstanding	15M	0
Mar 05, 2020	10-K filing \| 15.0M shares outstanding	15M	0

Back to KNSA Details